Imperial College London

Jiri Pavlu

Faculty of MedicineDepartment of Immunology and Inflammation

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 3313 8117j.pavlu Website

 
 
//

Location

 

Leuka Building R2.20Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

118 results found

Kishore B, Davis J, Rezvani K, Marin D, Chakrabartty J, Szydlo R, Loazia S, Chaidos A, Giles C, Kanfer E, Karadimitris A, Macdonald D, Milojkovic D, Rahemtulla A, Goldman J, Apperley J, Pavlu Jet al., 2012, Cryopreserved allogeneic peripheral blood stem cells result in outcome equivalent to those of fresh infusions enabling rational scheduling of donations, 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S253-S254, ISSN: 0268-3369

Conference paper

Chakrabartty J, Pavlu J, Neave EL, Eguialde ML, O'Shea D, Giles C, Goldman J, Kirschke S, Kanfer E, Kishore B, MacDonald D, Milojkovic D, Marin D, Rahemtulla A, Olavarria E, Apperley J, Rezvani Ket al., 2012, Safety and efficacy of two regimens of high-dose liposomal amphotericin B for prophylaxis of invasive fungal infection in allogeneic haematopoietic stem cell transplantation: a comparative retrospective single-centre study, 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S131-S131, ISSN: 0268-3369

Conference paper

Beckerson J, Sampson B, Kanfer E, Marin D, Milojkovic D, Pavlu J, Rahemtulla A, Rezvani K, Apperley J, Taylor Aet al., 2012, Plasma zinc, copper and selenium in subjects planned for haematopoietic stem cell transplant and their change during treatment, 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S192-S192, ISSN: 0268-3369

Conference paper

Pavlu J, Rezvani K, Kishore B, Chakrabartty J, Shah R, Auner HW, Milojkovic D, Marin D, Rahemtulla A, MacDonald DH, Kanfer EJ, Dazzi F, Goldman JM, Apperley JF, Szydlo RMet al., 2012, Optimising patient selection for allogeneic stem cell transplantation: prediction of non-relapse mortality and survival, 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S27-S28, ISSN: 0268-3369

Conference paper

Innes A, May PC, Pavlu J, Bain BJet al., 2012, Unexpected pancytopenia following treatment of acute lymphoblastic leukemia, AMERICAN JOURNAL OF HEMATOLOGY, Vol: 87, Pages: 412-412, ISSN: 0361-8609

Journal article

Auner HW, Pavlu J, Szydlo R, Giles C, Kanfer E, Macdonald D, Marin D, Milojkovic D, Rezvani K, Goldman JM, Apperley JF, Landgren O, Rahemtulla Aet al., 2012, Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 157, Pages: 125-127, ISSN: 0007-1048

Journal article

Rezvani K, Kanfer EJ, Marin D, Gabriel I, Rahemtulla A, Taylor A, MacDonald D, Dazzi F, Milojkovic D, Foroni L, Pavlu J, Sargent J, Le Dieu R, Goldman JM, Apperley J, Szydlo Ret al., 2012, EBMT Risk Score Predicts Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Who Have Failed a Previous Transplantation Procedure, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, Vol: 18, Pages: 235-240, ISSN: 1083-8791

Journal article

Al-Shieban S, Liu C, Fishlock K, May PC, Pavlu J, Naresh KNet al., 2012, Bone marrow trephine biopsy findings in acute promyelocytic leukemia., Am J Hematol, Vol: 87, Pages: 109-110

Journal article

Pavlu J, Rezvani K, Kishore B, Le Dieu R, Chakrabartty J, Chaidos A, Kanfer EJ, Karadimitris A, MacDonald DH, Marin D, Milojkovic D, O'Boyle F, Rahemtulla A, Slade D, Goldman JM, Apperley JF, Szydlo RMet al., 2011, Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation, 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, Publisher: AMER SOC HEMATOLOGY, Pages: 849-849, ISSN: 0006-4971

Conference paper

Kishore B, Davis J, Rezvani K, Marin D, Szydlo RM, Sandra L, Chrissy G, Chaidos A, Kanfer EJ, Karadimitris A, MacDonald DH, Milojkovic D, Rahemtulla A, Goldman JM, Apperley JF, Pavlu Jet al., 2011, Cryopreserved Allogeneic Peripheral Blood Stem Cells Result in Outcome Equivalent to Those of Fresh Infusions Enabling Rational Scheduling of Donations, 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, Publisher: AMER SOC HEMATOLOGY, Pages: 1730-1731, ISSN: 0006-4971

Conference paper

Innes AJ, Lurkins J, Szydlo RM, Guerra A, Milojkovic D, Pavlu J, Kanfer EJ, Marin D, MacDonald D, Rahemtulla A, Loaiza S, Kirschke S, Rezvani K, Goldman J, Apperley JF, Dazzi Fet al., 2011, The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission, 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, Publisher: AMER SOC HEMATOLOGY, Pages: 1752-1752, ISSN: 0006-4971

Conference paper

Pavlu J, Auner HW, Ellis S, Szydlo RM, Giles C, Contento A, Rahemtulla A, Apperley JF, Naresh K, MacDonald DH, Kanfer EJet al., 2011, LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre, HEMATOLOGICAL ONCOLOGY, Vol: 29, Pages: 75-80, ISSN: 0278-0232

Journal article

Pavlu J, Emmerson J, Marks AJ, Bain BJet al., 2011, Idiopathic cytopenia of undetermined significance and the minimal criteria for a diagnosis of myelodysplastic syndrome, LEUKEMIA & LYMPHOMA, Vol: 52, Pages: 515-516, ISSN: 1042-8194

Journal article

de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo R, Kanfer E, Macdonald D, Kelleher P, Cooper N, Khoder A, Gabriel IH, Milojkovic D, Pavlu J, Goldman JM, Apperley JF, Rezvani Ket al., 2011, Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host, HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol: 96, Pages: 307-314, ISSN: 0390-6078

Journal article

de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo R, Kanfer E, Macdonald D, Kelleher P, Cooper N, Khoder A, Gabriel IH, Milojkovic D, Pavlu J, Goldman JM, Apperley JF, Rezvani Ket al., 2011, Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host., Haematologica, Vol: 96, Pages: 307-314

BACKGROUND: In 2009 the declaration by the World Health Organization of a global pandemic of influenza-H1N1 virus led to a vaccination campaign to ensure protection for immunocompromised patients. The goal of this study was to determine the efficacy of the 2009 H1N1 vaccine in patients with hematologic malignancies. DESIGN AND METHODS: We evaluated humoral and cellular immune responses to 2009 H1N1 vaccine in 97 adults with hematologic malignancies and compared these responses with those in 25 adult controls. Patients received two injections of vaccine 21 days apart and the controls received one dose. Antibody titers were measured using a hemagglutination-inhibition assay on days 0, 21 and 49 after injection of the first dose. Cellular immune responses to H1N1 were determined on days 0 and 49. RESULTS: By day 21 post-vaccination, protective antibody titers of 1:32 or more were seen in 100% of controls compared to 39% of patients with B-cell malignancies (P<0.001), 46% of allogeneic stem cell transplant recipients (P<0.001) and 85% of patients with chronic myeloid leukemia (P=0.086). After a second dose, seroprotection rates increased to 68%, (P=0.008), 73%, (P=0.031), and 95% (P=0.5) in patients with B-cell malignancies, after allogeneic stem cell transplantation and with chronic myeloid leukemia, respectively. On the other hand, T-cell responses to H1N1 vaccine were not significantly different between patients and controls. CONCLUSIONS: These data demonstrate the efficacy of H1N1 vaccine in most patients with hematologic malignancies and support the recommendation for the administration of two doses of vaccine in immunocompromised patients. These results may contribute towards the development of evidence-based guidelines for influenza vaccination in such patients in the future.

Journal article

Pavlu J, Szydlo RM, Goldman JM, Apperley JFet al., 2011, Three decades of transplantation for chronic myeloid leukemia: what have we learned?, BLOOD, Vol: 117, Pages: 755-763, ISSN: 0006-4971

Journal article

Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni Let al., 2011, Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors, Journal of Clinical Oncology

Purpose We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular milestones that would predict for overall survival (OS) and other outcomes more reliably than serial marrow cytogenetics.Patients and Methods We analyzed 282 patients with CML-CP who received imatinib 400 mg/d as first-line therapy followed by dasatinib or nilotinib if treatment with imatinib failed. We used a receiver operating characteristic curve to identify the cutoffs in transcript levels at 3, 6, and 12 months that would best predict patient outcome. We validated our findings in an independent cohort of 95 patients treated elsewhere.Results Patients with transcript levels of more than 9.84% (n = 68) at 3 months had significantly lower 8-year probabilities of OS (56.9% v 93.3%; P < .001), progression-free survival, cumulative incidence of complete cytogenetic response, and complete molecular response than those with higher transcript levels. Similarly, transcript levels of more than 1.67% (n = 87) at 6 months and more than 0.53% (n = 93) at 12 months identified high-risk patients. However, transcript levels at 3 months were the most strongly predictive for the various outcomes. When we compared OS for the groups defined molecularly at 6 and 12 months with the usual cytogenetic milestones, categorization by transcript numbers was the only independent predictor for OS (relative risk, 0.207; P < .001 and relative risk, 0.158; P < .001, respectively).Conclusion A single measurement of BCR-ABL1 transcripts performed at 3 months is the best way to identify patients destined to fare poorly, thereby allowing early clinical intervention.

Journal article

Pavlu J, Shah R, Auner HW, Milojkovic D, Sargent DMJ, MacDonald ARDH, Kanfer EJ, Rezvani K, Dazzi F, Apperley JMGJF, Szydlo RMet al., 2010, Preconditioning Level of C Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Pages: 1433-1434, ISSN: 0006-4971

Conference paper

Pavlu J, Shah R, Auner HW, Milojkovic D, Marin D, Sargent J, Rahemtulla A, MacDonald DH, Kanfer EJ, Rezvani K, Dazzi F, Goldman JM, Apperley JF, Szydlo RMet al., 2010, Preconditioning Level of C-Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation, 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, Pages: 1433-1434, ISSN: 0006-4971

Conference paper

Holroyd A, Phillips E, Szydlo R, Marin D, Foroni L, Khorashad J, Milojkovic D, Kanfer EJ, Dazzi F, MacDonald DH, Rahemtulla A, McLornan D, Gabriel IH, Pavlu J, Sargent J, Goldman JM, Apperley JF, Rezvani Ket al., 2010, Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia, 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, Pages: 1445-1445, ISSN: 0006-4971

Conference paper

Chaidos A, Szydlo RM, Kanfer EJ, Dazzi F, MacDonald DH, Marin D, Milojkovic D, Pavlu J, Davis J, Rezvani K, Rahemtulla A, Roberts I, Apperley JF, Karadimitris Aet al., 2010, High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts., 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, Pages: 1051-1052, ISSN: 0006-4971

Conference paper

De Lavallade H, Garland PL, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo RM, Kanfer EJ, McDonald D, Kelleher P, Cooper N, Khoder A, Gabriel IH, Alsuliman A, Milojkovic D, Pavlu J, Goldman JM, Apperley JF, Rezvani Ket al., 2010, 2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies Requirement for Repeated Dosing to Optimize Seroprotec, Pages: 297-298, ISSN: 0006-4971

Conference paper

Holroyd A, Phillips E, Szydlo R, Mann D, Foroni L, Khorashad J, Milojkovic D, Kanfer EJ, Dazzi F, MacDonald DH, Rahemtulla A, McLornan D, Gabriel IH, Pavlu J, Sargent J, Goldman JM, Apperley JF, Rezvani Ket al., 2010, Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chrome Myeloid Leukemia, Pages: 1445-1445, ISSN: 0006-4971

Conference paper

de Lavallade H, Garland PL, Sekine T, Hoschler K, Marin D, Stringaris K, Loucaides E, Howe K, Szydlo RM, Kanfer EJ, McDonald D, Kelleher P, Cooper N, Khoder A, Gabriel IH, Alsuliman A, Milojkovic D, Pavlu J, Goldman JM, Apperley JF, Rezvani Ket al., 2010, 2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection, 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, Pages: 297-298, ISSN: 0006-4971

Conference paper

Naresh KN, Pavlu J, 2010, Plasmacytoid dendritic cell nodules in bone marrow biopsies of chronic myelomonocytic leukemia, AMERICAN JOURNAL OF HEMATOLOGY, Vol: 85, Pages: 893-893, ISSN: 0361-8609

Journal article

Pavlu J, Kew AK, Taylor-Roberts B, Auner HW, Marin D, Olavarria E, Kanfer EJ, MacDonald DH, Milojkovic D, Rahemtulla A, Rezvani K, Goldman JM, Apperley JF, Szydlo RMet al., 2010, Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase, BLOOD, Vol: 115, Pages: 4018-4020, ISSN: 0006-4971

Journal article

Garland P, de Lavallade H, Sekine T, Stringaris K, Loucaides E, Howe K, Kanfer E, Marin D, Apperley J, Milojkovic D, Macdonald D, Rahemtulla A, Pavlu J, Gabriel I, Khoder A, Alsuliman A, Bazeos A, Szydlo R, Cooper N, Rezvani Ket al., 2010, Severe 2009 H1N1 influenza in patients with haematological malignancies, 50th Annual Scientific Meeting of the British-Society-for-Haematology, Publisher: WILEY-BLACKWELL PUBLISHING, INC, Pages: 47-47, ISSN: 0007-1048

Conference paper

Pavlu J, Kew A, Taylor-Roberts B, Auner H, Kanfer E, MacDonald D, Marin D, Milojkovic D, Rahemtulla A, Rezvani K, Goldman J, Apperley J, Szydlo Ret al., 2010, Optimizing patient selection for myeloablative allogeneic haemopoietic cell transplantation in chronic myeloid leukaemia in chronic phase, 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, Publisher: NATURE PUBLISHING GROUP, Pages: S239-S239, ISSN: 0268-3369

Conference paper

Pavlu J, Auner H, Ellis S, Szydlo R, Giles C, McLornan D, Contento A, Rahemtulla A, Apperley J, Naresh K, MacDonald D, Kanfer Eet al., 2010, LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre, BONE MARROW TRANSPLANTATION, Vol: 45, Pages: S255-S255, ISSN: 0268-3369

Journal article

Porkka K, Pavlu J, Contento A, Mustjoki S, Olavarria E, Apperley Jet al., 2010, Tyrosine kinase inhibitor therapy is associated with a low risk of cytomegalovirus reactivation after allogeneic haematopoietic stem cell transplantation, 36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, Publisher: NATURE PUBLISHING GROUP, Pages: S38-S38, ISSN: 0268-3369

Conference paper

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: limit=30&id=00618900&person=true&page=3&respub-action=search.html